01311nas a2200253   4500000000100000008004100001260001300042653001600055653001900071653001100090653002500101653002900126653004500155653002100200653002200221653001800243100001600261700001800277245007200295300001000367490000700377520065900384022001401043       1995                            d  c1995 Feb10aClofazimine10aDNA, Bacterial10aHumans10aIntercalating Agents10aMycobacterium Infections10aMycobacterium Infections, Nontuberculous10aPhospholipases A10aPhospholipases A210aSkin Diseases1 aArbiser J L1 aMoschella S L00aClofazimine: a review of its medical uses and mechanisms of action.  a241-70 v323 a<p>Clofazimine has been in clinical use for almost 40 years, but little is known of its mechanism of action. The primary indication for clofazimine is multibacillary leprosy, but it is useful in several infectious and noninfectious diseases, such as typical myocobacterial infections, rhinoscleroma, pyoderma gangrenosum, necrobiosis lipoidica, severe acne, pustular psoriasis, and discoid lupus erythematosus. Postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2. Clinical experience, possible mechanisms of action, and side effects of clofazimine are summarized.</p>  a0190-9622